Johnson & Johnson Innovation - Jjdc 13F annual report
Johnson & Johnson Innovation - Jjdc is an investment fund managing more than $978 million ran by Sergio Calvo-regueros. There are currently 21 companies in Mr. Calvo-regueros’s portfolio. The largest investments include Fate Therapeutics Inc and Arrowhead Pharmaceuticals, together worth $563 million.
$978 million Assets Under Management (AUM)
As of 27th July 2021, Johnson & Johnson Innovation - Jjdc’s top holding is 3,379,064 shares of Fate Therapeutics Inc currently worth over $293 million and making up 30.0% of the portfolio value.
Relative to the number of outstanding shares of Fate Therapeutics Inc, Johnson & Johnson Innovation - Jjdc owns more than approximately 0.1% of the company.
In addition, the fund holds 3,260,869 shares of Arrowhead Pharmaceuticals worth $270 million, whose value fell 15.3% in the past six months.
The third-largest holding is Protagonist Therapeutics Inc worth $110 million and the next is Cvrx, Inc. worth $97.9 million, with 3,495,575 shares owned.
Currently, Johnson & Johnson Innovation - Jjdc's portfolio is worth at least $978 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Johnson & Johnson Innovation - Jjdc
The Johnson & Johnson Innovation - Jjdc office and employees reside in New Brunswick, New Jersey. According to the last 13-F report filed with the SEC, Sergio Calvo-regueros serves as the Assistant Treasurer at Johnson & Johnson Innovation - Jjdc.
Recent trades
In the most recent 13F filing, Johnson & Johnson Innovation - Jjdc revealed that it had opened a new position in
Cvrx, Inc. and bought 3,495,575 shares worth $97.9 million.
On the other hand, Sergio Calvo-regueros disclosed a decreased stake in Senseonics Inc by 0.9%.
This leaves the value of the investment at $210 thousand and 54,621 shares.
One of the average hedge funds
The two most similar investment funds to Johnson & Johnson Innovation - Jjdc are Blueshift Asset Management and Ledyard National Bank. They manage $978 million and $977 million respectively.
Sergio Calvo-regueros investment strategy
Johnson & Johnson Innovation - Jjdc’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 85.9% of
the total portfolio value.
The fund focuses on investments in the United States as
61.9% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
10% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.89 billion.
The complete list of Johnson & Johnson Innovation - Jjdc trades based on 13F SEC filings
These positions were updated on August 3rd based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Fate Therapeutics Inc |
No change
3,379,064
|
$293,269,000 | 29.98% |
| Arrowhead Pharmaceuticals Inc. |
No change
3,260,869
|
$270,065,000 | 27.61% |
| Protagonist Therapeutics Inc |
No change
2,449,183
|
$109,919,000 | 11.24% |
| Cvrx, Inc. |
Opened
3,495,575
|
$97,876,000 | 10.01% |
| Legend Biotech Corp |
No change
1,629,173
|
$66,878,000 | 6.84% |
| MeiraGTx Holdings plc |
No change
2,898,550
|
$44,928,000 | 4.59% |
| Fusion Pharmaceuticals Inc. |
No change
3,670,516
|
$29,658,000 | 3.03% |
| Vor Biopharma, Inc. |
No change
1,074,658
|
$20,042,000 | 2.05% |
| BiomX Inc |
No change
2,133,402
|
$11,648,000 | 1.19% |
| Therapeutics Acquisition Cor |
Opened
1,000,000
|
$10,274,000 | 1.05% |
| Adicet Bio, Inc. |
No change
728,944
|
$7,501,000 | 0.77% |
| PhaseBio Pharmaceuticals, Inc. |
No change
1,607,044
|
$5,978,000 | 0.61% |
| Aldeyra Therapeutics Inc |
No change
394,834
|
$4,473,000 | 0.46% |
| Castlight Health Inc |
No change
811,295
|
$2,134,000 | 0.22% |
| Neuropace, Inc. |
Opened
55,435
|
$1,319,000 | 0.13% |
| Zymergen Inc. |
Opened
16,553
|
$662,000 | 0.07% |
| TRACON Pharmaceuticals Inc |
No change
84,003
|
$545,000 | 0.06% |
| Catalyst Biosciences Inc |
No change
66,951
|
$290,000 | 0.03% |
| Graybug Vision, Inc. |
No change
49,547
|
$269,000 | 0.03% |
| Pulmonx Corp |
No change
5,639
|
$249,000 | 0.03% |
| Senseonics Holdings Inc |
88.90%
54,621
|
$210,000 | 0.02% |
| No transactions found | |||
| Showing first 500 out of 21 holdings | |||
Hedge funds similar to Johnson & Johnson Innovation - Jjdc
- Bard Services
- John F. Brennan, Jr
- Globalt
- Almanack Investment Partners,
- Cabana
- Sarissa Capital Management L.P.
- Greenbrier Partners Capital Management
- Blueshift Asset Management
- Ledyard National Bank
- Venrock Management V
- Accredited Investors
- Origin Asset Management LL.P.
- Tokio Marine Asset Management Co Ltd
- Lodestar Investment Counsel il